SEC Company Response from INNOCAN PHARMA (INNPF) — Jan 27, 2026
INNOCAN PHARMA Corp
Date: Jan. 27, 2026 · CIK: 0001889791 · Accession: 0001493152-26-003785
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288899
Letter
Innocan Pharma Corporation
1015, 926 – 5 Avenue SW
Calgary, Alberta T2P 0N7, Canada
January 27, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
RE: Innocan Pharma Corporation (CIK 0001889791)
Registration Statement No. 333-288899 on Form F-1 (the "Registration Statement")
Ladies and Gentlemen:
Innocan Pharma Corporation (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Securities Act "), so that it may become effective on January 29, 2026 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A., by calling David Huberman at 312.364.1633. The Company hereby authorizes Mr. Huberman to orally modify or withdraw this request for acceleration.
Very
truly yours,
INNOCAN
PHARMA CORPORATION
Show Raw Text
CORRESP 1 filename1.htm Innocan Pharma Corporation 1015, 926 – 5 Avenue SW Calgary, Alberta T2P 0N7, Canada January 27, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Innocan Pharma Corporation (CIK 0001889791) Registration Statement No. 333-288899 on Form F-1 (the "Registration Statement") Ladies and Gentlemen: Innocan Pharma Corporation (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Securities Act "), so that it may become effective on January 29, 2026 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable. The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A., by calling David Huberman at 312.364.1633. The Company hereby authorizes Mr. Huberman to orally modify or withdraw this request for acceleration. Very truly yours, INNOCAN PHARMA CORPORATION By: /s/ Iris Bincovich Iris Bincovich Chief Executive Officer